A Successful Treatment Approach in 2 Patients With Type 1 Plasminogen Deficiency: Intratracheal Application of Fresh Frozen Plasma and Tissue Plasminogen Activator

J Pediatr Hematol Oncol. 2023 Oct 1;45(7):423-426. doi: 10.1097/MPH.0000000000002698. Epub 2023 Jun 22.

Abstract

Background: Respiratory system involvement is common in congenital plasminogen deficiency. Although many treatment approaches have been tried, there is still no definitive treatment for respiratory system involvement.

Observations: We report 2 congenital plasminogen deficiency cases, who presented with severe respiratory symptoms, for whom a novel treatment modality was tried. After intravenous administration of FFP (fresh frozen plasma), tissue plasminogen activator and FFP were administered intratracheally, and respiratory system findings improved.

Conclusions: Intratracheal administration of tissue plasminogen activator and FFP is an available treatment modality for patients with lung involvement. Fibrin plaques should be carefully removed and new lesion formation should be prevented.

MeSH terms

  • Coagulation Protein Disorders*
  • Humans
  • Plasma
  • Plasminogen
  • Tissue Plasminogen Activator* / therapeutic use

Substances

  • Tissue Plasminogen Activator
  • Plasminogen

Supplementary concepts

  • Congenital Plasminogen Deficiency